|By PR Newswire||
|September 4, 2014 06:15 PM EDT||
WAYNE, Pa., Sept. 4, 2014 /PRNewswire-USNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the Eastern District of Pennsylvania on behalf of investors who acquired Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) securities during the period from September 10, 2013 through July 16, 2014 (the "Class Period").
Lannett shareholders may, no later than October 27, 2014, move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of Lannett and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/lci. You may also email Mr. Maniskas at [email protected].
Lannett develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company's business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) the Company was fixing, maintaining, and controlling prices of digoxin, a drug used to treat congestive heart failure, in violation of Connecticut antitrust laws; (2) the Company was allocating and dividing customers and territories with competitors relating to the sale of digoxin in violation of Connecticut antitrust laws; (3) the Company's anticompetitive practices subjected Lannett to heightened regulatory scrutiny, including possible investigation by the Connecticut Office of the Attorney General ("CTAG"); and (4) as a result of the foregoing, Lannett's public statements were materially false and misleading at all relevant times. As a result of defendants' alleged false and misleading statements, the Company's stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on July 16, 2014, the Company issued a press release and filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that the Company received interrogatories and a subpoena from the CTAG concerning its investigation into pricing and customer/territorial division of digoxin.
On this news, shares in Lannett plummeted more than 17%, closing at $39.04 per share on July 16, 2014, on unusually heavy trading volume.
If you are a member of the class, you may, no later than October 27, 2014, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
SOURCE Ryan & Maniskas, LLP
Dec. 6, 2016 01:00 AM EST Reads: 1,841
Dec. 6, 2016 12:45 AM EST Reads: 838
Dec. 6, 2016 12:30 AM EST Reads: 3,884
Dec. 6, 2016 12:30 AM EST Reads: 1,193
Dec. 6, 2016 12:30 AM EST Reads: 4,579
Dec. 6, 2016 12:00 AM EST Reads: 877
Dec. 5, 2016 11:45 PM EST Reads: 4,298
Dec. 5, 2016 10:45 PM EST Reads: 2,075
Dec. 5, 2016 10:30 PM EST Reads: 1,055
Dec. 5, 2016 10:30 PM EST Reads: 981
Dec. 5, 2016 09:00 PM EST Reads: 4,960
Dec. 5, 2016 08:45 PM EST Reads: 507
Dec. 5, 2016 07:45 PM EST Reads: 2,229
Dec. 5, 2016 07:45 PM EST Reads: 2,090
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Dec. 5, 2016 07:15 PM EST Reads: 403